REVB · Revelation Biosciences, Inc.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the grant date.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

Represents the weighted-average price at which shares were purchased within a range between $1.14 and $1.17. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The stock options vest and become exercisable on the grant date.

The stock options vest and become exercisable on the grant date.

The stock options vest and become exercisable on the grant date.

The stock options vest and become exercisable on the grant date.

The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date.

The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date.

Represents the weighted-average price at which shares were purchased within a range between $2.53 and $2.57. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

The original Form 4, filed on February 8, 2022, is being amended by this Form 4 amendment to include shares purchased directly that were inadvertently omitted in the original filing.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

In connection with Petra Acquisition, Inc.'s business combination, all shares were redeemed for cash at $10.20 per share, which is equal to the pro rata share of the aggregate amount in the Company's trust account.

The Common Stock is directly owed by Feis Equities LLC. Lawrence Feis, as the Managing Member of Feis Equities LLC will also be deemed to beneficially own the shares.

The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.

The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.

The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein.

On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering.

The reporting person is a member of Petra Investment Holdings, LLC ("Sponsor"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC.